Bavarian Nordic upgrades again following new batch of monkeypox contracts

The vaccine maker last adjusted its financial expectation on Friday, and followed up with newer target figures on Monday due to even more orders for its smallpox vaccine, Jynneos.
Photo: Lukas Barth/Reuters/Ritzau Scanpix
Photo: Lukas Barth/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

Bavarian Nordic has just upgraded its financial outlook for 2022 again, coming not long after the last time the vaccine maker saw the opportunity to do so.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading